Thus, Gleevec treatment of a Notch-4-ICD or Int3 positive mammary tumors/estrogen negative would be expected to be associated with proteasome-mediated degradation of P105, inhibition of NF-κB canonical pathway and subsequent remission of mammary tumor growth. Here, NOTCH4 is linked to breast cancer.